GSK

1,418

-2.88%↓

HLN.UK

384.3

-2.71%↓

INDV

712

-3.26%↓

GSK

1,418

-2.88%↓

HLN.UK

384.3

-2.71%↓

INDV

712

-3.26%↓

GSK

1,418

-2.88%↓

HLN.UK

384.3

-2.71%↓

INDV

712

-3.26%↓

GSK

1,418

-2.88%↓

HLN.UK

384.3

-2.71%↓

INDV

712

-3.26%↓

GSK

1,418

-2.88%↓

HLN.UK

384.3

-2.71%↓

INDV

712

-3.26%↓

Search

AstraZeneca PLC

Fermé

SecteurSoins de santé

10,842 -4.66

Résumé

Variation du prix de l'action

24h

Actuel

Min

10840

Max

10920

Chiffres clés

By Trading Economics

Revenu

237M

1.7B

Ventes

1.3B

15B

P/E

Moyenne du Secteur

32.661

63.778

BPA

2.09

Rendement du dividende

2.18

Marge bénéficiaire

11.188

Employés

94,300

EBITDA

-235M

4.4B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+21.16% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.18%

2.39%

Prochains Résultats

29 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.8B

179B

Ouverture précédente

10846.66

Clôture précédente

10842

Sentiment de l'Actualité

By Acuity

44%

56%

146 / 386 Classement par Healthcare

AstraZeneca PLC Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 mars 2025, 03:15 UTC

Principaux Mouvements du Marché

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17 mars 2025, 07:42 UTC

Acquisitions, Fusions, Rachats

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

3 avr. 2025, 08:41 UTC

Market Talk

Big Pharma Left Uncertain About U.S. Tariff Risk -- Market Talk

3 avr. 2025, 08:36 UTC

Market Talk

U.K. Pharma to Have Some Share-Price Volatility But Long-Term Outlook Remains Intact -- Market Talk

3 avr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

31 mars 2025, 09:31 UTC

Actions en Tendance

Stocks to Watch Monday: Nvidia, Tesla, Robinhood, Tokyo Electron -- WSJ

17 mars 2025, 14:43 UTC

Market Talk

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17 mars 2025, 13:55 UTC

Market Talk
Acquisitions, Fusions, Rachats

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17 mars 2025, 07:04 UTC

Acquisitions, Fusions, Rachats

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17 mars 2025, 07:03 UTC

Acquisitions, Fusions, Rachats

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17 mars 2025, 07:03 UTC

Acquisitions, Fusions, Rachats

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17 mars 2025, 07:01 UTC

Acquisitions, Fusions, Rachats

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17 mars 2025, 07:01 UTC

Acquisitions, Fusions, Rachats

AstraZeneca Buying EsoBiotec for up to $1B

17 mars 2025, 07:01 UTC

Acquisitions, Fusions, Rachats

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17 mars 2025, 07:00 UTC

Acquisitions, Fusions, Rachats

AstraZeneca to Buy EsoBiotec

28 févr. 2025, 12:00 UTC

Actualités

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 févr. 2025, 14:59 UTC

Market Talk

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26 févr. 2025, 08:04 UTC

Market Talk
Résultats

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20 févr. 2025, 11:34 UTC

Acquisitions, Fusions, Rachats

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 févr. 2025, 11:34 UTC

Acquisitions, Fusions, Rachats

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 févr. 2025, 11:33 UTC

Acquisitions, Fusions, Rachats

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 févr. 2025, 11:33 UTC

Acquisitions, Fusions, Rachats

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 févr. 2025, 11:31 UTC

Acquisitions, Fusions, Rachats

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 févr. 2025, 11:30 UTC

Acquisitions, Fusions, Rachats

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13 févr. 2025, 10:49 UTC

Market Talk
Résultats

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7 févr. 2025, 10:30 UTC

Actualités

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 févr. 2025, 15:18 UTC

Market Talk

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6 févr. 2025, 13:24 UTC

Market Talk

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6 févr. 2025, 12:01 UTC

Résultats

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6 févr. 2025, 11:22 UTC

Market Talk
Résultats

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

Comparaison

Variation de prix

AstraZeneca PLC prévision

Objectif de Prix

By TipRanks

21.16% hausse

Prévisions sur 12 Mois

Moyen 13,802.5 GBX  21.16%

Haut 19,000 GBX

Bas 10,900 GBX

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

10

Achat

4

Maintien

0

Vente

Sentiment

By Acuity

146 / 386Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.